Meeting
2022 ASCO Annual Meeting
Checkpoint inhibitor consolidation after definitive chemoradiation for stage III non–small cell lung cancer: Real-world experience in a large academic health system.
Authors
Nikhil Yegya-Raman
University of Pennsylvania, Philadelphia, PA
Nikhil Yegya-Raman , Cole Friedes , Lova Sun , Melina Elpi Marmarelis , William C. Levin , Keith A. Cengel , Brian Lally , Christopher Davella , John A. Kosteva , Aditi Puri Singh , Roger B. Cohen , Charu Aggarwal , Christine Ciunci , Abigail T. Berman , Corey J. Langer , Steven J. Feigenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8523)
DOI
10.1200/JCO.2022.40.16_suppl.8523
Abstract #
8523
Poster Bd #
150
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Statewide rates of adjuvant checkpoint inhibitor use after definitive chemoradiation for stage III non-small cell lung cancer.
First Author: Alex K. Bryant
Poster
2022 ASCO Annual Meeting
Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.
First Author: Jarushka Naidoo
Poster
2021 ASCO Annual Meeting
AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).
First Author: Helen J. Ross
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto